Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local Manufacture of CAR T-Cells for B-Cell Malignancies
NCT05281809Phase 2Recruiting
- Start
- Apr 2022
- Primary completion
- Aug 2037
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Anti-CD19 CAR T-cells (Beijing Doing Biomedical) in B cell lymphoma, B cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL). Started Apr 2022; status: recruiting.
02
Drugs
Anti-CD19 CAR T-cells (Beijing Doing Biomedical)
03
Conditions
B cell lymphomaB cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05281809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281809.